Phase 3 Trial Underway to Assess Gilteritinib as Maintenance Therapy in Certain AML Patients
News
The first participant has begun treatment in a new Phase 3 clinical trial assessing Astellas Pharma‘s gilteritinib as a maintenance therapy for certain acute myeloid leukemia (AML) patients who are in remission ... Read more